Nemvaleukin Alfa + Pembrolizumab Earn Fast Track Designation for Ovarian Cancer
source: pixabay.com

Nemvaleukin Alfa + Pembrolizumab Earn Fast Track Designation for Ovarian Cancer

Sometimes, treatments used in conjunction with each other can confer benefits for patients. According to the Cancer Network, for example, treating platinum-resistant ovarian cancer using nemvaleukin alfa and pembrolizumab (Keytruda)…

Continue Reading Nemvaleukin Alfa + Pembrolizumab Earn Fast Track Designation for Ovarian Cancer

A New Collaboration Could Bring A New CLN2 Batten Disease Treatment To Patients Faster

LEXEO Therapeutics and FUJIFILM Diosynth Biotechnologies have just announced their collaborative partnership. The aim is to develop and ultimately manufacture the AAV-mediated gene therapies developed by LEXEO. LEXEO LEXEO is…

Continue Reading A New Collaboration Could Bring A New CLN2 Batten Disease Treatment To Patients Faster